文献速递神经胸部MR

影像组学预测EGFR-TKI疗效:基于转移灶/脑实质界面

Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.
PubMed 文献 · Radiol Med · 2022-10-25

研究纳入中心1的230例和中心2的80例NSCLC脑转移患者,利用治疗前增强T1和T2 MRI将瘤周水肿区分为亚区,提取影像组学特征建模。基于转移灶/脑实质界面亚区与肿瘤活动区联合模型预测EGFR突变训练AUC 0.945,外部验证AUC 0.895;预测TKI反应外部验证AUC 0.802,提示亚区影像组学可辅助治疗决策。

要点

  • 基于转移灶/脑实质界面亚区影像组学可预测EGFR突变状态。
  • 联合模型预测TKI反应外部验证AUC为0.802。
  • 需治疗前增强T1和T2 MRI进行亚区划分与特征提取。

核心结论

  • 亚区影像组学可提供EGFR状态和TKI反应互补信息,模型有望指导NSCLC脑转移治疗计划。

研究设计与样本

  • 研究纳入中心1的230例和中心2的80例患者,分别作为训练/内部验证和外部验证队列。
  • 患者治疗前接受增强T1加权和T2加权MRI扫描。
  • 采用个体和群体水平聚类将瘤周水肿区划分为表型一致的亚区。
  • 从肿瘤活动区、瘤周水肿区及亚区提取并筛选影像组学特征建模。
  • 用ROC曲线和Delong检验比较各区域预测价值。

诊断标准与关键数值

  • 预测EGFR突变,多区域联合模型EGFR-Fusion在训练集AUC=0.945、SEN=0.878、SPE=0.937。
  • EGFR-Fusion在内部验证集AUC=0.880、SEN=0.733、SPE=0.969。
  • EGFR-Fusion在外部验证集AUC=0.895、SEN=0.875、SPE=0.800。
  • 预测EGFR-TKI反应,TKI-Fusion模型训练集AUC=0.869、SEN=0.717、SPE=0.884。
  • TKI-Fusion模型内部验证AUC=0.786、SEN=0.708、SPE=0.818;外部验证AUC=0.802、SEN=0.750、SPE=0.800。

临床应用与阅片要点

  • 阅片时需关注瘤周水肿区,尤其转移灶/脑实质界面,作为亚区影像组学分析基础。
  • 治疗前增强T1和T2 MRI是模型应用的必要序列,确保图像质量满足特征提取。
  • 模型输出可辅助预测EGFR突变和TKI反应,但需结合临床信息综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the potential of subregional radiomics as a novel tumor marker in predicting epidermal growth factor receptor (EGFR) mutation status and response to EGFR-tyrosine kinase inhibitor (TKI) therapy in NSCLC patients with brain metastasis (BM).

MATERIALS AND METHODS: We included 230 patients from center 1, and 80 patients were included from center 2 to form a primary and external validation cohort, respectively. Patients underwent contrast-enhanced T1-weighted and T2-weighted MRI scans before treatment. The individual- and population-level clustering was used to partition the peritumoral edema area (POA) into phenotypically consistent subregions. Radiomics features were calculated and selected from the tumor active area (TAA), POA and subregions, and used to develop models. Prediction values of each region were investigated and compared with receiver operating characteristic curves and Delong test.

RESULTS: For predicting EGFR mutations, a multi-region combined model (EGFR-Fusion) was developed based on joint of the partitioned metastasis/brain parenchyma (M/BP)-interface and TAA, and generated the highest prediction performance in the training (AUC = 0.945, SEN = 0.878, SPE = 0.937), internal validation (AUC = 0.880, SEN = 0.733, SPE = 0.969), and external validation (AUC = 0.895, SEN = 0.875, SPE = 0.800) cohorts. For predicting response to EGFR-TKI, the developed multi-region combined model (TKI-Fusion) yielded predictive AUCs of 0.869 (SEN = 0.717, SPE = 0.884), 0.786 (SEN = 0.708, SPE = 0.818), and 0.802 (SEN = 0.750, SPE = 0.800) in the training, internal validation and external validation cohort, respectively.

CONCLUSION: Our study revealed that complementary information regarding the EGFR status and response to EGFR-TKI can be provided by subregional radiomics. The proposed radiomics models may be new markers to guide treatment plans for NSCLC patients with BM.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Fan, Zhao, Wang, et al. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface. Radiol Med. 2022. PMID: 36284030. doi:10.1007/s11547-022-01569-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。